Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ALT-801 |
Synonyms | |
Therapy Description |
ALT-801 is comprised of IL-2 fused to a T-cell receptor domain that targets p53, potentially enhancing immune response to p53-expressing tumor cells and resulting in increased tumor cell death (PMID: 21994418). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ALT-801 | p53 Vaccine 5 | ALT-801 is comprised of IL-2 fused to a T-cell receptor domain that targets p53, potentially enhancing immune response to p53-expressing tumor cells and resulting in increased tumor cell death (PMID: 21994418). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01326871 | Phase Ib/II | ALT-801 | A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer | Completed | USA | 0 |
NCT01625260 | Phase Ib/II | ALT-801 ALT-801 + Gemcitabine | A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer | Terminated | USA | 0 |